Benefits of 5-FU Dose Optimization

With OnDose™, 5-FU Dosing Can Be Optimized

The current standard of care for dosing — body surface area (BSA) — does not account for many of the factors that impact 5-FU metabolism and efficacy. Some of these factors include genotype, age, gender, disease state, drug-drug interactions, organ function, and comorbidities. Despite its widespread use, BSA accounts for only 2 of these factors - height and weight.¹

A recent study showed that up to 85% of patients may not be dosed optimally.^2,3*

With optimized dosing, there are proven benefits for both efficacy and toxicity²

• Optimized dosing provided significantly greater objective response rates (33.7% versus 17.3% with BSA-based dosing; P=.004)²

• Despite having higher mean doses of 5-FU,† patients experienced significantly less toxicity (P=.003)²
  • Patients experienced a 78% reduction in grades 3/4 diarrhea²

• Optimized dosing demonstrated a trend toward incresed median survival²
  • 22 months versus 16 months with BSA-based dosing (P=.08)²

OnDose provides a report that gives you the data you need to help optimize your patient's infusional 5-FU dose. Using the supplied OnDose data, you can make dose adjustments of infusional 5-FU to help optimize therapy for your patient's next cycle of chemotherapy and help maximize efficacy and minimize toxicity.

^*Based on data underlying Gamelin et al.
^†1500 mg/m² with BSA-based dosing versus mean of 1790 mg/m² with optimized dosing.²

References:
1. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol. 1990;8(10):1739-1753.
2. Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(13):2099-2105.
3. Data on file, Myriad Genetic Laboratories, Inc., Salt Lake City, UT.
4. Gamelin E, Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer - status of the art. Crit Rev Oncol Hematol. 1999;30(1):71-79.

Myriad Genetic Laboratories, Inc.
320 Wakara Way, Salt Lake City, UT 84108

1-800-469-7423 | E-mail: ondose@myriad.com
Myriad, the Myriad logo, OnDose, and the OnDose logo are either trademarks or registered trademarks of Myriad Genetics, Inc., in the United States and other jurisdictions.

>> Testing Process

>> Order a Test

>> Information on Theraguide^® 5FU, a personalized medicine product to predict toxicity to 5FU-based chemotherapy